Skip to main content

Dyne Therapeutics, Inc.

DYN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001818794

In the last 90 days, Dyne Therapeutics, Inc. insiders filed 0 open-market purchases and 11 sales; 245 institutions reported holding it in 13F filings for Q2 2026, worth $4.23B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Dyne Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
11 filings
6 insiders, $100.9M in total
Insiders trading
6
Net value
−$100.9M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Dyne Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Dyne Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Friedl-Naderer JohannaChief Commercial Officer152,897Sep 8, 20267
Kerr DouglasChief Medical Officer162,564Sep 8, 20267
Cox JohnCEO & President357,507Sep 8, 20267
Rhodes Jason PDirector428,946IndirectAug 17, 20269
Lucera ErickChief Financial Officer119,766Aug 17, 20265
Kersten DirkDirector3,586,796IndirectJul 29, 20269
Greene Barry EDirector–Jun 23, 20261
Hurwitz EdwardDirector–Jun 9, 20261
Posner Brian SDirector24,500Jun 9, 20268
Lubner David CharlesDirector0Jun 9, 20262
Stehman-Breen CatherineDirector–Jun 9, 20261
Incerti CarloDirector0Jun 9, 20261
Karnani VikramDirector–Dec 23, 20251
Scalzo Richard WilliamSVP, Head of Finance & Admin.122,330Mar 13, 20250
Beskrovnaya OxanaChief Scientific Officer195,840Mar 13, 20250
High Susanna GattiChief Operating Officer131,636Sep 19, 20240
McNeill JonathanChief Business Officer132,106Aug 20, 20240
Farwell WildonChief Medical Officer143,222Aug 20, 20240
Brumm Joshua TCEO & President537,998Mar 12, 20240
Atlas Venture Opportunity Fund I, L.P.10% Owner847,388IndirectMar 5, 20240
Atlas Venture Associates Opportunity I, L.P.10% Owner847,388IndirectMar 5, 20240
Atlas Venture Associates Opportunity I, LLC10% Owner847,388IndirectMar 5, 20240
Atlas Venture Opportunity Fund II, L.P.10% Owner847,388IndirectMar 5, 20240
Atlas Venture Associates Opportunity II, LLC10% Owner847,388IndirectMar 5, 20240
Atlas Venture Associates Opportunity II, LP10% Owner847,388IndirectMar 5, 20240
Atlas Venture Fund XI, L.P.10% Owner864,487IndirectFeb 28, 20240
Atlas Venture Associates XI, LLC10% Owner864,487IndirectFeb 28, 20240
Atlas Venture Associates XI, L.P.10% Owner864,487IndirectFeb 28, 20240
Klein Lawrence OttoDirector–Jul 6, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 8, 2026 (view filing)4:15 PM ETSep 4-84 daysFriedl-Naderer JohannaChief Commercial OfficerSSale−1.08K$23.42−$25.4K−0.7%152.9K after2 lots10b5-1
Sep 8, 2026 (view filing)4:14 PM ETSep 4-84 daysKerr DouglasChief Medical OfficerSSale−5.04K$22.95−$115.5K−3.0%162.6K after2 lots10b5-1
Sep 8, 2026 (view filing)4:13 PM ETSep 8Same dayCox JohnCEO & PresidentSSale−5.66K$18.88−$106.8K−1.6%357.5K after10b5-1
Aug 17, 2026 (view filing)5:30 PM ETAug 13-144 daysRhodes Jason PDirectorSSale−2.59M$25.20−$65.2M−85.8%428.9K after6 lots10b5-1
Aug 17, 2026 (view filing)4:08 PM ETAug 134 daysFriedl-Naderer JohannaChief Commercial OfficerSSale−226$26.28−$5.94K−0.1%154.0K after10b5-1
Aug 17, 2026 (view filing)4:08 PM ETAug 134 daysKerr DouglasChief Medical OfficerSSale−1.56K$26.28−$40.9K−0.9%167.6K after10b5-1
Aug 17, 2026 (view filing)4:07 PM ETAug 134 daysCox JohnCEO & PresidentSSale−4.99K$26.28−$131.0K−1.4%363.2K after10b5-1
Aug 17, 2026 (view filing)4:06 PM ETAug 134 daysLucera ErickChief Financial OfficerSSale−1.80K$26.28−$47.2K−1.5%119.8K after10b5-1
Jul 29, 2026 (view filing)4:15 PM ETJul 272 daysKersten DirkDirectorSSale−261.5K$25.51−$6.67M−6.8%3.59M after2 lots10b5-1
Jul 8, 2026 (view filing)5:35 PM ETJul 6-72 daysRhodes Jason PDirectorSSale−777.5K$22.97−$17.9M−99.6%2.96K after10 lots10b5-1
Jun 30, 2026 (view filing)Jun 26-294 daysRhodes Jason PDirectorSSale−504.7K$21.23−$10.7M−34.1%975.9K after6 lots10b5-1
Jun 26, 2026 (view filing)Jun 23-253 daysLateRhodes Jason PDirectorSSale−267.8K$21.09−$5.65M−19.9%1.08M after9 lots10b5-1
Jun 26, 2026 (view filing)Jun 251 dayLucera ErickChief Financial OfficerSSale−2.36K$20.37−$48.1K−1.9%121.6K after
Jun 24, 2026 (view filing)Jun 22-232 daysKersten DirkDirectorSSale−264.0K$20.70−$5.46M−6.4%3.85M after3 lots10b5-1
Jun 22, 2026 (view filing)Jun 17-185 daysKersten DirkDirectorSSale−84.4K$20.10−$1.70M−2.0%4.11M after2 lots10b5-1
Jun 17, 2026 (view filing)Jun 161 dayFriedl-Naderer JohannaChief Commercial OfficerSSale−145$18.33−$2.66K−0.1%154.2K after10b5-1
Jun 17, 2026 (view filing)Jun 161 dayKerr DouglasChief Medical OfficerSSale−887$18.33−$16.3K−0.5%169.2K after10b5-1
Jun 17, 2026 (view filing)Jun 161 dayCox JohnCEO & PresidentSSale−2.68K$18.33−$49.2K−0.7%368.2K after10b5-1
Jun 9, 2026 (view filing)Jun 81 dayPosner Brian SDirectorPPurchase+2.00K$16.94+$33.9K+8.9%24.5K after
Jun 5, 2026 (view filing)Jun 32 daysPosner Brian SDirectorPPurchase+2.50K$17.48+$43.7K+12.5%22.5K after
May 28, 2026 (view filing)May 262 daysPosner Brian SDirectorPPurchase+2.00K$18.21+$36.4K+11.1%20.0K after
May 22, 2026 (view filing)May 202 daysPosner Brian SDirectorPPurchase+2.50K$17.12+$42.8K+16.1%18.0K after
May 14, 2026 (view filing)May 131 dayFriedl-Naderer JohannaChief Commercial OfficerSSale−228$18.36−$4.19K−0.1%154.4K after10b5-1
May 14, 2026 (view filing)May 131 dayKerr DouglasChief Medical OfficerSSale−1.56K$18.36−$28.7K−0.9%170.0K after10b5-1
May 14, 2026 (view filing)May 131 dayLucera ErickChief Financial OfficerSSale−1.45K$18.36−$26.6K−1.2%123.9K after10b5-1
May 14, 2026 (view filing)May 131 dayCox JohnCEO & PresidentSSale−3.31K$18.36−$60.8K−0.9%370.8K after10b5-1
May 6, 2026 (view filing)May 4-62 daysRhodes Jason PDirectorSSale−106.7K$18.14−$1.94M−8.6%1.14M after12 lots10b5-1
Apr 30, 2026 (view filing)Apr 282 daysRhodes Jason PDirectorSSale−227.3K$18.38−$4.18M−16.4%1.16M after8 lots10b5-1
Apr 27, 2026 (view filing)Apr 23-274 daysRhodes Jason PDirectorSSale−384.5K$18.47−$7.10M−24.2%1.21M after12 lots10b5-1
Apr 23, 2026 (view filing)Apr 21-222 daysKersten DirkDirectorSSale−11.0K$20.01−$219.1K−0.3%4.20M after2 lots10b5-1
Apr 22, 2026 (view filing)Apr 20-222 daysRhodes Jason PDirectorSSale−834.3K$19.75−$16.5M−39.4%1.29M after16 lots10b5-1
Apr 21, 2026 (view filing)Apr 17-204 daysKersten DirkDirectorSSale−337.2K$20.21−$6.82M−7.4%4.21M after2 lots10b5-1
Apr 17, 2026 (view filing)Apr 15-162 daysKersten DirkDirectorSSale−99.6K$20.35−$2.03M−2.1%4.54M after3 lots10b5-1
Apr 3, 2026 (view filing)Apr 12 daysLucera ErickChief Financial OfficerSSale−5.73K$18.64−$106.8K−4.4%125.4K after10b5-1
Apr 1, 2026 (view filing)Mar 302 daysPosner Brian SDirectorPPurchase+2.00K$17.08+$34.2K+14.8%15.5K after
Mar 13, 2026 (view filing)Mar 112 daysPosner Brian SDirectorPPurchase+2.00K$19.35+$38.7K+17.4%13.5K after
Mar 13, 2026 (view filing)Mar 112 daysKersten DirkDirectorSSale−129.7K$19.52−$2.53M−2.7%4.64M after10b5-1
Mar 11, 2026 (view filing)Mar 9-102 daysKersten DirkDirectorSSale−688.8K$19.09−$13.2M−12.6%4.77M after4 lots10b5-1
Mar 10, 2026 (view filing)Mar 64 daysPosner Brian SDirectorPPurchase+3.00K$15.06+$45.2K+35.3%11.5K after
Mar 6, 2026 (view filing)Mar 51 dayFriedl-Naderer JohannaChief Commercial OfficerSSale−148$14.90−$2.21K−0.1%154.6K after10b5-1
Mar 6, 2026 (view filing)Mar 51 dayKerr DouglasChief Medical OfficerSSale−904$14.90−$13.5K−0.5%171.6K after10b5-1
Mar 6, 2026 (view filing)Mar 51 dayCox JohnCEO & PresidentSSale−2.73K$14.90−$40.7K−0.7%374.1K after10b5-1
Dec 5, 2025 (view filing)Dec 5Same dayCox JohnCEO & PresidentSSale−2.66K$20.72−$55.2K−1.3%196.9K after10b5-1
Dec 5, 2025 (view filing)Dec 5Same dayKerr DouglasChief Medical OfficerSSale−880$20.72−$18.2K−1.0%87.5K after10b5-1
Dec 5, 2025 (view filing)Dec 5Same dayFriedl-Naderer JohannaChief Commercial OfficerSSale−144$20.72−$2.98K−0.2%94.7K after10b5-1
Sep 9, 2025 (view filing)Sep 54 daysCox JohnCEO & PresidentSSale−2.64K$13.41−$35.4K−1.3%199.5K after10b5-1
Sep 8, 2025 (view filing)Sep 4-54 daysFriedl-Naderer JohannaChief Commercial OfficerSSale−1.04K$13.29−$13.8K−1.1%94.9K after2 lots10b5-1
Sep 8, 2025 (view filing)Sep 4-54 daysKerr DouglasChief Medical OfficerSSale−4.42K$13.30−$58.8K−4.8%88.4K after2 lots10b5-1
Jul 15, 2025 (view filing)Jul 141 dayCox JohnCEO & PresidentPPurchase+100.0K$9.11+$911.0K+70.3%242.2K after
Jun 6, 2025 (view filing)Jun 51 dayCox JohnCEO & PresidentSSale−4.06K$13.35−$54.2K−2.8%142.2K after10b5-1